Methoflex500 mg

Methoflex is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions.

• Established use: Short-term adjunctive therapy for acute muscle spasm and pain of musculoskeletal origin (e.g., low back pain, muscle strain), used together with rest and physiotherapy - not as a sole treatment.
• Additional established use (injectable formulation): As an adjunct to other measures in the supportive management of muscle spasm associated with tetanus, under specialist/hospital care.

Methoflex does not act directly on skeletal muscle, the motor endplate, or the nerve fiber; its benefit is thought to result from generalized central nervous system depression.

Each tablet of Methocarbamol typically contains Methocarbamol USP 500 mg or 750 mg as the active ingredient, along with pharmaceutically approved excipients. An injectable solution (Methocarbamol 100 mg/mL) is available in some markets for hospital use.

Methoflex is a carbamate derivative of guaifenesin belonging to the centrally-acting skeletal muscle relaxant class. It is used as a short-term adjunct to rest, physical therapy, and other supportive measures to relieve discomfort from acute, painful musculoskeletal conditions. Methoflex is available as oral tablets and, in hospital settings, as an injectable solution.

Centrally-Acting Skeletal Muscle Relaxant

Methocarbamol is a centrally-acting skeletal muscle relaxant. Its precise mechanism of action in humans has not been fully established, but its clinical effect is believed to result from general central nervous system (CNS) depression rather than any direct relaxant action on skeletal muscle, the motor endplate, or nerve conduction.

After oral administration, Methocarbamol is well absorbed from the gastrointestinal tract, with peak plasma concentrations reached within about 1 to 2 hours. It is extensively metabolized in the liver via dealkylation and hydroxylation, and the metabolites are eliminated mainly through the kidneys, along with a small amount of unchanged drug. Plasma protein binding is approximately 46-50%, and the elimination half-life is roughly 1 to 2 hours in individuals with normal renal and hepatic function.

Take Methoflex tablets orally, swallowed whole with a full glass of water, with or without food. If stomach upset occurs, taking it with food or milk may help. The injectable form of Methoflex is given only by a healthcare professional via slow intravenous infusion or intramuscular injection. Do not drive or operate machinery until you know how Methoflex affects you.

Methoflex has the following well-documented clinically significant interactions:

• CNS depressants and alcohol: Concurrent use with alcohol, sedatives, opioids, benzodiazepines, or other CNS depressants can produce additive sedation, drowsiness, and impaired coordination; combinations should be used cautiously, if at all.
• Anticholinesterase agents (e.g., pyridostigmine): Methoflex may inhibit the effect of anticholinesterase agents; use with caution in patients with myasthenia gravis receiving these drugs.
• Laboratory test interference: Methoflex may interfere with certain color-reaction laboratory tests (e.g., for 5-hydroxyindoleacetic acid [5-HIAA] and vanillylmandelic acid [VMA]), potentially causing false results; inform your laboratory/physician if you are taking Methoflex.

Always inform your physician or pharmacist of all medicines, supplements, and alcohol use before starting Methoflex.

Side effects associated with Methoflex are usually mild and dose-related.

Common

• Drowsiness, dizziness, light-headedness
• Blurred vision, headache
• Nausea, stomach upset
• Mild muscular incoordination
• Metallic taste, nasal congestion
• Harmless discoloration of urine (black, brown, or green) - an expected, benign effect that resolves after stopping the drug

Less common/serious

• Skin rash, itching, urticaria (allergic-type reactions)
• Fever
• Seizures (particularly in patients with seizure disorders)
• Fainting/syncope, low blood pressure (especially with rapid intravenous administration of the injectable form)
• Injection-site reactions, such as pain, swelling, or thrombophlebitis (injectable form only)
• Rarely, jaundice or reduced white blood cell counts

Seek medical attention if you experience signs of a serious allergic reaction (swelling of the face/throat, difficulty breathing) or any severe or persistent side effect while taking Methoflex.

Methoflex is classified under the older FDA pregnancy category C. Teratogenic effects have been observed in some animal studies, and adequate, well-controlled studies in pregnant women are lacking. Methoflex should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus; use only if clearly needed and after consulting a physician.

It is not known whether Methoflex or its metabolites pass into human breast milk in clinically significant amounts. Because of the potential for sedation in a nursing infant, caution is advised, and a physician should be consulted before using Methoflex while breastfeeding.

Observe the following precautions when using Methoflex:

• Sedation/CNS effects: Methoflex commonly causes drowsiness and dizziness; avoid driving or operating hazardous machinery until you know how it affects you. Effects are additive with alcohol and other CNS depressants - see Interactions.
• Urine discoloration: Methoflex may cause the urine to turn black, brown, or green; this is a harmless, expected effect that does not indicate organ damage.
• Injectable formulation: Rapid intravenous administration may cause hypotension, bradycardia, syncope, flushing, or a metallic taste; injection-site reactions (pain, phlebitis) can occur with IV/IM use. The injectable form should be given slowly and only by trained healthcare personnel, with the patient lying down.
• Renal considerations: See Contraindications regarding the injectable formulation in renal pathology; use tablets cautiously in significant renal impairment.
• Seizure disorders: Use with caution in patients with a history of seizures, as CNS-depressant effects may be relevant.
• Not for long-term use: Methoflex is intended for short-term adjunctive therapy of acute muscle spasm; it is not intended for chronic, prolonged use. Reassess the need for continued therapy with a physician.
• Elderly patients: May be more sensitive to the sedative effects of Methoflex; use the lowest effective dose.

Overdose of Methoflex may cause nausea, drowsiness, blurred vision, hypotension, seizures, and, in severe cases, coma. Combination with alcohol or other CNS depressants can increase the risk and severity of overdose effects.

If an overdose of Methoflex is suspected, seek immediate medical attention or contact a poison control center/emergency services right away. Treatment is supportive and may include maintaining the airway, monitoring vital signs, and other measures provided by medical professionals; there is no specific antidote for Methoflex overdose. Do not attempt to manage a suspected overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric use: The safety and efficacy of Methoflex for acute musculoskeletal spasm have not been established in children under 16 years of age; it is not generally recommended for this indication in this age group. Pediatric use of the injectable form for tetanus, when required, is determined by a specialist based on weight and clinical judgment.

Elderly: Older adults may be more susceptible to the sedative and CNS-depressant effects of Methoflex; use the lowest effective dose and monitor closely for dizziness, drowsiness, or falls.

Renal impairment: Drug clearance may be reduced; use oral Methoflex with caution and avoid the injectable formulation in known or suspected renal pathology (see Contraindications).

Hepatic impairment: Clearance is reduced and the elimination half-life is prolonged in significant hepatic impairment; use a reduced dose with caution and close monitoring.

Methoflex is generally used short-term, typically for no more than 2 to 3 weeks, as an adjunct to rest and physical therapy for acute muscle spasm. If symptoms persist beyond this period, consult a physician to reassess treatment; Methoflex is not intended for long-term or chronic use.

Centrally-Acting Skeletal Muscle Relaxants; Carbamate derivative of guaifenesin

The exact mechanism of action of Methocarbamol has not been fully established in humans. It does not act directly on skeletal muscle fibers, the motor endplate, or the nerve fiber. Its muscle-relaxant and analgesic-adjunct effect is thought to result from general central nervous system depression.

C

Safety and efficacy of Methoflex for acute musculoskeletal spasm have not been established in children under 16 years of age. Use of the injectable form for tetanus in pediatric patients, when indicated, should be guided by a specialist and based on body weight.